medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Number 2

<< Back Next >>

Rev Mex Neuroci 2007; 8 (2)

Toxicological treatment of the intoxication syndromes and psychotropic abstinence

Souza MM, Cruz ML, Díaz BSL, Guisa CVM

Language: Spanish
References: 171
Page: 170-188
PDF size: 108.87 Kb.


ABSTRACT

The disorders produced by substance consumption show a serious impact: from 20 to 50% of the hospitalized patients; from 15 to 30% of the ones handled in first level, and 50% of those with psychiatric disorders. In the emergency rooms, intoxication and withdrawal syndromes are rarely investigated with ad hoc clinical histories, nor is considered its diagnosis, comorbidity or pharmacologic/psychotherapeutic needs in the long term. Most of the abusers/addicts remain undiagnosed, and the patients who have not received treatment and suffer chronic pain or anxiety/depressive disorders are in high risk of getting comorbid pathology. The allocation of correct handling has been restricted by the lack of training of the therapeutic equipment in the field of addictions, in clear contrast with the other critical procedures. The acute treatment for these symptoms is almost never offered based in individual needs and their medical indication; the administration is assigned and altered by different institutional and/or personal adversities which go from administrative issues to the contratransferential ones. This paper offers from a schematic point of view, a quick guide, in the context of “the best practices” of prompt attention addressed to the health personnel to favor its treatment, derived from a better reference-reception of the cases. The advance of neurosciences has favored a better and clearer notion of the problem. It facilitates, as well, therapeutic handlings through an each time more efficient praxis. Its tripartite character, scientific, technical, and humanistic must not be missed.


REFERENCES

  1. Betz C, Mihalic D, Pinto ME, Raffa RB. Could a common biochemical mechanism underlie addictions? J Clin Pharm Ther 2000; 25: 11-20.

  2. Blum K, Braverman ER, Holder MM. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000; 32(Suppl.): 1-112.

  3. Slutske WS, Eisen S, True WR, Lyons MJ, Goldberg J, Tsuang M. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000; 57: 666-73.

  4. Potenza MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry 2001; 6: 217-26.

  5. Feigelman W, Wallisch LS, Lesieur HR. Problem gamblers, problem substance users, and dual problem individuals: an epidemiological study. Am J Public Health 1998; 88: 467-70.

  6. Organización Mundial de la Salud, OMS. Décima Revisión Internacional de la Clasificación de Enfermedades. Capítulo Quinto. Desórdenes Mentales, Conductuales y del Desarrollo. OMS, Ginebra, Suiza; 1993.

  7. American Psychiatric Association, APA. Diagnostical and Statistical Manual of Mental Disorders, DSM-IV-TR. Washington; 2000.

  8. Shaffer HJ, Laplante DA, Labrie RA, Kidman RC, Donato AN, Stanton MV. Toward a Syndrome Model of Addiction: Multiple Expressions, Common Etiology. Harv Rev Psychiatry 2004; 12: 367-74.

  9. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004; 12: 305-20.

  10. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003; 160: 687-95.

  11. Hyman SE, Fenton WS. What are the right targets for psychopharmacology? Science 2003; 299: 350-1.

  12. Souza y MM. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Rev Mex Neuroci 2003; 4(5): 326-30.

  13. Shaffer HJ, Korn DA. Gambling and related mental disorders: A public health analysis. Annu Rev Public Health 2002; 23: 171-212.

  14. Kendler KS, Liu XQ, Gardner CO, McCullough ME, Larson D, Prescott CA. Dimensions of religiosity and their relationship to lifetime psychiatric and substance use disorders. Am J Psychiatry 2003; 160: 496-503.

  15. Merikangas KR, Stolar M, Stevens DE. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55: 973-9.

  16. Bierut LJ, Dinwiddie SH, Begleiter H. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: A report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 2002; 59: 153.

  17. Wechsler H, Davenport AE, Dowdall GW, Grossman SJ, Zanakos SI. Binge drinking, tobacco, and illicit drug use and involvement in college athletics. A survey of students at 140 American colleges. J Am Coll Health 1997; 45: 195- 200.

  18. Laplante DA, Labrie RA, Kidman RC, Donato AN, Stanton MV. Toward a Syndrome Model of Addiction: Multiple Expressions, Common Etiology. Harv Rev Psychiatry 2004; 12: 367-74.

  19. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.

  20. Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13.

  21. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159: 1642-52.

  22. Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 2002; 26: 321-52.

  23. Morris JS, Dolan RJ. Involvement of human amygdala and orbitofrontal cortex in hunger-enhanced memory for food stimuli. J Neurosci 2001; 21: 5304-10.

  24. Zahm DS. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 2000; 24: 85-105.

  25. Winder DG, Egli RE, Schramm NL, Matthews RT. Synaptic plasticity in drug reward circuitry. Curr Mol Med 2002; 2: 667-76.

  26. Bush G, Vogt BA, Holmes J, Dale AM, Greve D, Jenike MA, Rosen BR. Dorsal anterior cingulate cortex: a role in reward-based decision making. Proc Natl Acad Sci USA 2002; 99: 523-8.

  27. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999; 146: 373-90.

  28. Thomas MJ, Beurrier C, Bonci A, Malenka RC. Long-term depression in the nucleus accumbens: A neural correlate of behavioral sensitization to cocaine. Nat Neurosci 2001; 4: 1217-23.

  29. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003; 54: 25-53.

  30. O’Brien C. Drug addiction and drug abuse. In: The Pharmacological Basis of Therapeutics. Edited by Hardman J, Limbird L, Gilman AG. N.Y.: McGraw-Hill; 2001, pp. 621-42.

  31. Mogenson GJ, Brudzynski SM, Wu M, Yang CR, Yim CCY. From motivation to action: A review of dopaminergic regulation of limbic-nucleus accumbens-pedunculopontine nucleus circuitries involved in limbic-motor integration, in Limbic Motor Circuits and Neuropsychiatry. In: Kalivas PW, Barnes CD. Eds. Boca Raton, Fla,: CRC Press; 1993, pp. 193-236.

  32. Sánchez-Hervás E, Molina N, Del Olmo R, Tomás V, Morales E. Craving y adicción a drogas. Trastornos Adictivos 2001; 3: 237-43.

  33. Souza y MM. Nosología y propedéutica de los programas antiadictivos. Rev. Mex. Neuroci. 2005; 6(2): 166-79.

  34. Guisa CVM, Díaz Barriga SL, Souza y MM. Terapéutica antiadictiva. utilidad de sus factores de predicción. Rev Mex Neuroci 2004; 5(6): 581-98.

  35. Souza y MM. Diagnóstico y Tratamiento de los Síndromes Adictivos. México: Editorial Ciencia y Cultura Latinoamérica; 2000.

  36. Souza y MM, Guisa CVM, Díaz Barriga SL. Hacia una integración nacional de la terapéutica antiadictiva. Rev Mex Neuroci 2005; 6(5): 411-25.

  37. SSA, CONADIC, INPRFM; DGE; INEGI. Encuesta Nacional de Adicciones 2002. México; 2003.

  38. Miller NS. Comorbid of psychiatric and alcohol/drug disorder: Interactions and dependent status. J Addict Dis 1993; 12(3): 5-16.

  39. Ratey JJ. Paying attention to attention in adults. Chadder 1991; Fall/Winter: 13-4.

  40. Gold MS, Miller NS, Stennie K, Populla-Vardi C. Epidemiology of benzodiazepine use and dependence. Psychiatric Annals 1995; 25: 146-8.

  41. Sanguinetti VR, Samuel SE. Comorbid substance abuse and recovery from acute psychiatric relapse. Hosp Community Psychiat 1998; 44(11): 1073-6.

  42. Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. J Am Med Assoc 1990; 264: 2511-18.

  43. Roache JD, Meisch RA. Findings from self-administration research on the addiction potential of benzodiazepines. Psychiatric Annals 1995; 25(3): 153-7.

  44. Longo LP. Non-benzodiazepine pharmacotherapy of anxiety and panic in substance abusing patients. Psychiatric Annals 1998; 28(3): 142-53.

  45. Souza y MM. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 57-69.

  46. Souza y MM, Martínez AJ, Mercado CG. Consideraciones sobre la Farmacoterapia del alcoholismo. Psiquiatría 1999; 2; 5(1): 12-19.

  47. Souza y MM, Mestas AJ, Turull TF, Cárdenas AJ. Historia Clínica Psiquiátrica Codificada para Alcoholismo, HCPCA. Una aportación al manejo asistencial del alcoholismo. Sal Púb Méx 1985; 17(4): 291-307.

  48. Miller NS, Ninonuevo FG, Klamen DL, Hoffmann NG, Smith DE. Integration of treatment and posttreatment variables in predicting results of abstinence-based outpatient treatment after one year. J Psychoactive Drugs 1997; 29(3): 239-48.

  49. Heinrich CJ, Lynn LE. Improving the organization, management, and outcomes of substance abuse treatment programs. Am J Drug Alcohol Abuse 2002; 28(4): 601-22.

  50. Committee on Addictions of the Group for the Advancement of Psychiatry. Responsability and options in drug addiction. Psychiatry Services 2002; 53: 707-13.

  51. Linares PMC, Palau MC, Albiach CC, Santos DP. Predictive variables of adherence to treatment in alcoholics. Actas Esp Psiquiatr 2002; 30(6): 370-5.

  52. Souza y MM. Programa profesional terapéutico contra las adicciones. Una propuesta integrativa. Psiquiatría 2005; Época 2, 21(1): 25-37.

  53. Souza y MM. Una mirada reflexiva a la terapéutica de las adicciones. Subdirección de Hospitalización y Proyectos Clínicos. Centros de Integración Juvenil, A.C.

  54. Souza y MM. Por una psiquiatría de las adicciones. Editorial. Rev Mex Neuroci 2003; 4(4): 206-8.

  55. Souza y MM, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI. Craving, adicción etílica y terapéutica. México. Arch Neurociencias 2000; 5(4): 201-4.

  56. Souza y MM. La deficiencia formativa del personal de salud y la terapéutica de las adicciones. Revista Mexicana de Prevención y Readaptación Social 2000; 8: 99-106.

  57. Guisa CVM, Díaz Barriga SL, Souza y MM. La Educación médica en adicciones y sus problemas. Psiquiatría 2004; Época 2, 20(1): 9-20.

  58. Souza y MM. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuroci 2001; 2(1): 25-7.

  59. Souza y MM. Profesionalización de la terapéutica antiadictiva. Simposio Nuevas Estrategias de Abordaje de las Adicciones. XIX Congreso Nacional. Asociación Psiquiátrica Mexicana, A.C. “Fortaleciendo lazos abriendo horizontes”. La Psiquiatría y sus Vínculos como Especialidad Médica. Los Cabos, Baja California Sur. Octubre 29-2 de Noviembre, 2005.

  60. Oficina de las Naciones Unidas Contra la Droga y el Delito (ONUDD). Abuso de drogas: tratamiento y rehabilitación. Guía de planificación y aplicación. Capítulo VI. Integración efectiva de los servicios de tratamiento. Naciones Unidas. Viena, 2003.

  61. Guisa CVM, Díaz Barriga SL, Souza y MM. El Alcoholismo en México. Rev Mex Neuroci 2004; 5(4): 356-64.

  62. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-95.

  63. Souza y MM, Díaz Barriga SL, Guisa CVM. Criterios derivativos para la referencia y tratamiento de abusadores/ adictos a psicotrópicos. México: Subdirección de Hospitalización y Proyectos Clínicos. Centros de Integración Juvenil, A.C.; 2006.

  64. Souza y MM, Quijano BEM, Díaz Barriga S, Guisa CVM, Lorenzo AS, Gaucin RR. Historia clínica psiquiátrica codificada para adicciones. 2a Época. HCPCA. Psiquiatría 1998; 14(1): 9-25.

  65. Matijasevic E. Nuevas fronteras en toxicología. In: Matijasevic E, Restrepo G (eds.). Séptimo Curso Anual de Actualizaciones en Medicina Interna. Bogotá: Ediciones Acta Médica Colombiana; 1994, p. 288-301.

  66. Barranco RF, Blasco MJ, Muñoz SMA, Jareño CHA. Principios de urgencias, emergencias y cuidados críticos. En: Gil CJ, Díaz-Alersi R, Coma JMA, Gil BD (eds.). www.uninet.edu/tratado/c100302.html.

  67. Escobar A. El retorno de la neurología y la psiquiatría a la neuropsiquiatría. Rev Mex Neuroci 2005; 6(6): 478-9.

  68. Vanderschuren LJ, Everitt BJ. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 2004; 305: 1017-19.

  69. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000; 10: 318-25.

  70. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19: 591-611.

  71. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28: 309-69.

  72. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000; 25: 515-32.

  73. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004; 55: 113-32.

  74. Wolf ME, Mangiavacchi S, Sun X. Mechanisms by which dopamine receptors may influence synaptic plasticity. Ann NY Acad Sci 2003; 1003: 241-9.

  75. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156: 11-18.

  76. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward: the role of amygdala-ventral striatal subsystems. Ann NY Acad Sci 1999; 877: 412-38.

  77. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2: 695-703.

  78. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60: 929-37.

  79. White NM. Addictive drugs as reinforcers: multiple partial actions on memory systems. Addiction 1996; 91: 921-49.

  80. Berke JD. Learning and memory mechanisms involved in compulsive drug use and relapse. Methods Mol Med 2003; 79: 75-101.

  81. Chklovskii DB, Mel BW, Svoboda K. Cortical rewiring and information storage. Nature 2004; 431: 782-8.

  82. Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addictionlike behavior in the rat. Science 2004; 305: 1014-17.

  83. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 1998; 12: 54-67.

  84. Dudai Y. Molecular bases of long-term memories: a question of persistence. Curr Opin Neurobiol 2002; 12: 211-16.

  85. Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1998; 1: 304-9.

  86. Kauer JA. Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. Annu Rev Physiol 2004; 66: 447-75.

  87. Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004; 44: 161-79.

  88. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-8.

  89. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001; 24: 167-202.

  90. Montague PR, Berns GS. Neural economics and the biological substrates of valuation. Neuron 2002; 36: 265-84.

  91. Montague PR, Dayan P, Sejnowski TJ. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J Neurosci 1996; 16: 1936-47.

  92. Montague PR, Hyman SE, Cohen JD. Computational roles for dopamine in behavioural control. Nature 2004; 431: 760-7.

  93. Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 2002; 78: 637-47.

  94. Rhee SH, Hewitt JK, Young SE, Corley RP, Crowley TJ, Stallings MC. Genetic and environmental influences on substance initiation, use, and problem use in adolescents. Arch Gen Psychiatry 2003; 60: 1256-64.

  95. Rolls ET. The functions of the orbitofrontal cortex. Brain Cogn 2004; 55: 11-29.

  96. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997; 275: 1593-9.

  97. Steven E, Hyman MD. I Addiction: A Disease of Learning and Memory. Am J Psychiatry 2005; 162: 1414-22.

  98. Vernon DD. Poisoning and drug overdose. Crit Care Clin 1997; 13(3): 647-67.

  99. Oficina de Política Nacional para el Control de Drogas (2001). Estrategia Nacional para el Control de Drogas: Informe Anual 2001.

  100. ONU. Tendencias Mundiales de las Drogas Ilícitas 2003. Publicación de la Oficina contra la droga y el delito de las Naciones Unidas. Nueva York: 2003.

  101. Zealberg JJ, Brady KT. Substance abuse and emergency psychiatry. Psychiatr Clin North Am 1999; 22: 803-17.

  102. Ian RH, Putnam SL, Jia H, Smith GS. Assessing substance abuse treatment need: A statewide hospital emergency department study. Annals of Emergency Medicine 2003; 41(6): 802-13.

  103. American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1995; 25(4): 570-85.

  104. Souza y MM. Filosofía y políticas de los programas terapéuticos contra las adicciones. Subdirección de Hospitalización y Proyectos Clínicos. Centros de Integración Juvenil, A.C. México, 2004.

  105. Ellenhorn MJ, Barceloux DG. Medical Toxicology. N.Y.: Elsevier; 1988, p. 67.

  106. Snodgrass WR. Clinical toxicology. In: Klaassen CD (ed.). Casaret & Doull’s Toxicology. 5th Ed. N.Y.: McGraw-Hill; 1996, p. 969-86.

  107. Ellenhorn M. Medical toxicology. Diagnosis and treatment of human poisoning. William and Wilkins; 1997.

  108. SAMHSA. Substance Abuse and Mental Health Services Administration. Office of Applied Studies, Summary of findings from 1998 National Household Survey on Drug Abuse, 1998.

  109. Wesson DR. Detoxification from alcohol and other drugs. Treatment Improvement Protocol (TIP) Series 19, Consensus Panel Chair, U.S. Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration, Printed 1995.

  110. Piola JC, Prada DB. Aspectos médicos toxicológicos en pacientes con adicción a drogas atendidos en Rosario. En: Adicciones, desafíos y abordajes. Salud en el Municipio de Rosario. El Rosario, Argentina: Ed. Secretaría de Salud Pública; 1998, p. 105-10.

  111. Gueye PN, Hoffman JR, Taboulet P. Empiric use of flumazenil in comatose patients: limited applicability of criteria to define low risk. Ann Emerg Med; 27: 730-5.

  112. Meredith TJ, Jacobsen D, Haines JA, Berger JC. Eds. Naloxone, flumazenil and dantrolene as antidotes. Cambridge: University Press; 1993.

  113. Kosten TH. Managment of Drug Alcohol withdrawal. N Eng J Med 2003; 348: 1786-95.

  114. Souza y MM. Personalidad y adicciones. Rev Mex Neuroci 2005; 6(4): 336-45.

  115. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y MM. Por qué profesionalizar la terapéutica de las adicciones. Época 2. Psiquiatría 2000; 16(3): 110-16.

  116. Blanco EA, Cea CL, García GME, Menassa A, Moreno CVJ, Muñoz DG, Olalla J, Varona JF. Manual de diagnóstico y terapéutica médica. 5a. Ed. Madrid: Hospital Universitario 12 de Octubre; 2003.

  117. Souza y MM. Curso Básico de Adicciones. Centros de Integración Juvenil, A, C. México: Instituto de Asistencia e Integración Social, IASIS. Gobierno del Distrito Federal; Noviembre 11-15, 2002.

  118. Hales RE, Yudofsky SC, Talbott JA. Tratado de Psiquiatría. 3th. Ed. American Psychiatric Press-Masson, Multimedia 2000.

  119. Castro LI, López AM. Técnicas de sondaje nasogástrico. En: Castro LI Coord (ed.). Guía de Actuación en Atención Primaria. 2a Ed. Barcelona: SMY; 2002, p. 1256-8.

  120. Quintana JL, De la Morena E, Artuñedo P. Sondaje nasogástrico. En: Arribas JM, Caballero F (eds.). Manual de cirugía menor y otros procedimientos en la consulta del médico de familia. Madrid: Merck Sharp & Dohme de España; 1993, p. 433-7.

  121. Souza y MM. Enseñanza e investigación en adicciones en la Ciudad de México. Época 2. Psiquiatría 1998; 14(3): 100-6.

  122. Olivares HM, Tagle OI, Mercado CG, Souza y MM. Psicodinamia y psicoterapia del paciente adicto. 2a. Época. Psiquiatría 2003; 19(1): 28-38.

  123. Souza y MM, Díaz Barriga SL, Guisa CVM. Adicciones: neuroquímica y terapéutica. Rev Mex Neuroci 2004; 5(6): 619-34.

  124. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry. 7a. Ed. Washington: William and Wilkins; l994.

  125. Goodman and Gillman. Las bases farmacológicas de la terapéutica. 9a. Ed. McGraw-Hill & Interamericana; 1996.

  126. Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J. Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35(5): 159-64.

  127. Kutz I, Reznik V. Heroin detoxification with a single high dose of buprenorphine. Isr J Psychiatry Relat Sci 2002; 39(2): 113-19.

  128. Souza y MM, Díaz Barriga SL, Guisa CVM. Terapéutica sustitutiva con buprenorfina para abusadores/adictos a opiáceos. Subdirección de Hospitalización y Proyectos Clínicos; Centros de Integración Juvenil, A.C. México, 2006.

  129. 129.SHAMSA. Opioid drugs in maintenance and detoxification treatment of opiate addiction. 2001; Jan 17; 66(11): 4076-102.

  130. Velasco MA. Farmacología Fundamental. Cap. 2-3. En: Velasco Martín A, San Román R, Martínez Sierra I. Cadavid. McGraw-Hill; 2003.

  131. Lorenzo P. Farmacología Básica y Clínica. Cap. 1. En: Lorenzo P, Moreno JC, Leza A y col. 17a. Ed. Panamericana; 2004.

  132. Azanza JR. Guía Práctica de Farmacología del SNC. Madrid: IM&C; 1997.

  133. 133.Jaffe JH, Knapp CM, Ciraulo DA. Opiates: Clinical Aspects. Lowinson JH, Ruiz P, Millman RB, Langrod JG. Substance Abuse. 3rd. Ed. Vol. 14. Williams & Wilkins; 1997, p. 158-16.

  134. Vilaseca Canals J, Espinàs Boquet J (eds.). Guía terapéutica en atención primaria. Basada en la evidencia. 2a. Ed. Barcelona: SEM FYC; 2004.

  135. American Society of Addiction Medicine, ASAM. Public policy statement on screening for addiction in primary care settings. ASAM News 1997; 17: 17-18.

  136. Chang G, Kosten TR. Detoxification. In: Substance abuse. A comprehensive Textbook. 3rd. Ed. Williams & Wilkins; 1997.

  137. Kilts CD, Gross RE, Ely TD, Drexler KPG. The neural correlates of cue-induced craving in cocaine-dependent women. Am J Psychiatry 2004; 161: 233-41.

  138. Enoch MA, Goldman D. Problem drinking and alcoholism: Diagnosis and treatment. Am Fam Physician 2002; 65(3): 449-50.

  139. Nogue Xarau I. Intoxicación por benzodiacepinas, antidepresivos, fenotiazinas y barbitúricos. Medicina Integral 1992; 20: 495-500.

  140. 140.Goldberg MJ, Berlinger WG. Treatment of phenobarbital overdose with activated charcoal. JAMA 1982; 247: 2400-5.

  141. Zawada ET, Nappi J, Done G. Advances in the hemodialysis management of phenobarbital overdose. South Med J 1983; 7: 6-14.

  142. Petry NM. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend 2000; 58: 9-25.

  143. O’Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998; 338: 592-602.

  144. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278: 144-51.

  145. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 349-55.

  146. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001; 10(Suppl.): 16-23.

  147. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001; 25: 1324-9.

  148. Palestine ML, Alatorre E. Control of acute alcoholic withdrawal symptoms: A comparative study of haloperidol and chlordiazepoxide. Curr Ther Res Clin Exp 1976; 20: 289-99.

  149. Nolla SJ, Roca TA. Motivo de ingreso y aspectos clínicos de la intoxicación aguda grave. Med Intensiva 1988; 12: 525-32.

  150. Spivey WH. Flumazenil and seizures: Analysis of 43 cases. Clin Ther 1992; 14: 978-86.

  151. Smith DE, Wesson DR. Benzodiazepines and other sedative hypnotics. In: Galanter M, Kleber HD (Eds.). The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press; 1999, pp. 239-50.

  152. Ashton CH. Las benzodiacepinas: Cómo actúan en el organismo. En: Ashton CH. Las benzodiacepinas: Cuál es su mecanismo de acción y cómo suspender la ingestión. Capítulo 1. Manual Ashton; 2002.

  153. Prado GA, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI, Souza y MM. Adicciones y farmacoterapia: uso de bupropión en la dependencia a cocaína. 2a. Época. Psiquiatría 2001; 17(2): 58-64.

  154. Commitee to Study Medication Developtment and Research at National Institute on Drug Abuse. In: Fulco CE, Liverment CT, Earley LE (eds.). The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Goverment and Private Sector. Washington, DC: National Academy Press; 1995.

  155. NIDA. Principios de tratamientos para la drogadicción, una guía basada en investigaciones. NIDA; 2001, p. 1.

  156. Kosten TR. Pathophysiology and treatment of cocaine dependence. In: Davis K, Charney D, Coyle JT, Nemeroff C (eds.). Neuropsychopharmacology: the fifth generation of progress. Baltimore: Lippincott Williams & Wilkins; 2002, p. 1461-73.

  157. Carelli RM, Wondolowski J. Selective encoding of cocaine versus natural rewards by nucleus accumbens neurons is not related to chronic drug exposure. J Neurosci 2003; 23: 11214-23.

  158. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine- induced reinstatement of drug-seeking behavior. J Neurosci 2003; 23: 3531-7.

  159. Kozell B, Meshul K. Alterations in nerve terminal glutamate immunoreactivity in the nucleus accumbens and ventral tegmental area following single and repeated doses of cocaine. Psychopharmacology (Berl) 2003; 165: 337-45.

  160. Schnoll SH. Drogadicción, sobredosis y síndrome de abstinencia. En: Ayres SM, Ake G, Holbrook PR, Shoemaker WC (eds.). Tratado de medicina crítica y terapia intensiva. Buenos Aires: Editorial Médica Panamericana; 1996, p. 1203-4.

  161. Moscovitz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8: 1-4.

  162. Alterman AI, Droba M, Antelo RE. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31: 19-29.

  163. O’Connor PG. Treating opioid dependence - new data and new opportunities. N Engl J Med 2000; 343: 1332-4.

  164. Kleber HD. Opioids: Detoxification. In: Galanter M, Kleber HD (eds.). The American Psychiatric Press textbook of substance abuse treatment. 2nd Ed. Washington, D.C.: American Psychiatric Press; 1999, p. 251-69.

  165. Nutt D. Alcohol and the brain: pharmacological insights for psychiatrists. Br J Psychiatry 1999; 175: 114-19.

  166. Oficina de las Naciones Unidas Contra la Droga y el Delito, PNUFID. Tratamiento contemporáneo del abuso de drogas: análisis de las pruebas científicas. N.Y.: ONU; 2003.

  167. Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors. J Addict Dis 1998; 17: 67-81.

  168. Wong C, Swanson JM. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003; 23: 11461-8.

  169. O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133: 40-54.

  170. Fiellin DA, O’Connor PG. Office-based treatment of opioiddependent patients. N Engl J Med 2002; 347: 817-23.

  171. Carroll KM. Relapse prevention as a psychosocial treatment approach: a review of controlled clinical trials. Exp Clin Psychopharm 1996; 4: 46-54.




2020     |     www.medigraphic.com